Matches in Wikidata for { <http://www.wikidata.org/entity/Q91629325> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q91629325 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q91629325 description "im Juli 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91629325 description "scientific article published on 05 July 2019" @default.
- Q91629325 description "wetenschappelijk artikel" @default.
- Q91629325 description "наукова стаття, опублікована 5 липня 2019" @default.
- Q91629325 name "Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre" @default.
- Q91629325 name "Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre" @default.
- Q91629325 type Item @default.
- Q91629325 label "Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre" @default.
- Q91629325 label "Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre" @default.
- Q91629325 prefLabel "Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre" @default.
- Q91629325 prefLabel "Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre" @default.
- Q91629325 P1433 Q91629325-7151427F-BAB4-417B-81A5-1EC85D38944C @default.
- Q91629325 P1476 Q91629325-4FA1B3A6-54E1-4177-BECB-B81CFF5A9DC8 @default.
- Q91629325 P2093 Q91629325-1812E272-BC3E-42F7-84EC-3EC1511BAF42 @default.
- Q91629325 P2093 Q91629325-A3301387-C68D-40F0-8AAD-62BAA69CEC89 @default.
- Q91629325 P2093 Q91629325-A692FF9B-E8D0-420C-BF65-011DBF1BCF20 @default.
- Q91629325 P2093 Q91629325-BED2B4F9-7AA2-4330-B1B4-487E5089D5D7 @default.
- Q91629325 P2093 Q91629325-BF21B695-999C-4D41-846B-A204D9364491 @default.
- Q91629325 P304 Q91629325-ED291B82-5EC9-476E-8613-826D2FC0FF99 @default.
- Q91629325 P31 Q91629325-E1A585E0-D790-4B05-B703-D9E412A10BC3 @default.
- Q91629325 P356 Q91629325-E58E716A-BFB6-4533-94BE-C23F1D54EED4 @default.
- Q91629325 P433 Q91629325-A962BE00-693F-4CD3-808D-756A3CF7BCDF @default.
- Q91629325 P478 Q91629325-33CC8C69-E4A8-4866-9A80-E91308F1860B @default.
- Q91629325 P50 Q91629325-25FB3253-F5DF-4922-A57B-1A15BAB9E0C3 @default.
- Q91629325 P50 Q91629325-A0BEA401-8179-4A97-A403-478465507A12 @default.
- Q91629325 P50 Q91629325-D8C5827E-A721-4ABD-9AF2-8CCC72A4AB0E @default.
- Q91629325 P50 Q91629325-F7D92933-1EC3-4FA9-95E9-B7DD22FCFEC8 @default.
- Q91629325 P577 Q91629325-0B5BC9DB-B5B5-4A57-9EBC-0630F8509B9F @default.
- Q91629325 P698 Q91629325-50304D2D-9D80-438B-8897-DC5549FA1702 @default.
- Q91629325 P356 EP.A2019.0023 @default.
- Q91629325 P698 31274183 @default.
- Q91629325 P1433 Q9253923 @default.
- Q91629325 P1476 "Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study" @default.
- Q91629325 P2093 "Antoine Tabarin" @default.
- Q91629325 P2093 "Carla Scaroni" @default.
- Q91629325 P2093 "Francesco M Minuto" @default.
- Q91629325 P2093 "Jan Komorowski" @default.
- Q91629325 P2093 "Veronique Kerlan" @default.
- Q91629325 P304 "305-312" @default.
- Q91629325 P31 Q13442814 @default.
- Q91629325 P356 "10.5603/EP.A2019.0023" @default.
- Q91629325 P433 "4" @default.
- Q91629325 P478 "70" @default.
- Q91629325 P50 Q22442888 @default.
- Q91629325 P50 Q58446548 @default.
- Q91629325 P50 Q64495559 @default.
- Q91629325 P50 Q93141235 @default.
- Q91629325 P577 "2019-07-05T00:00:00Z" @default.
- Q91629325 P698 "31274183" @default.